University of Rhode Island

DigitalCommons@URI
Open Access Master's Theses
2020

INVESTIGATING THE STRUCTURE AND FUNCTION OF A NOVEL
ANTI-VIRULENCE FACTOR
Jamie Wandzilak
University of Rhode Island, jamie_wandzilak@uri.edu

Follow this and additional works at: https://digitalcommons.uri.edu/theses

Recommended Citation
Wandzilak, Jamie, "INVESTIGATING THE STRUCTURE AND FUNCTION OF A NOVEL ANTI-VIRULENCE
FACTOR" (2020). Open Access Master's Theses. Paper 1890.
https://digitalcommons.uri.edu/theses/1890

This Thesis is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion
in Open Access Master's Theses by an authorized administrator of DigitalCommons@URI. For more information,
please contact digitalcommons@etal.uri.edu.

INVESTIGATING THE STRUCTURE AND FUNCTION OF
A NOVEL ANTI-VIRULENCE FACTOR
BY
JAMIE WANDZILAK

A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE
REQUIREMENTS FOR THE DEGREE OF
MASTER OF SCIENCE
IN
CELL AND MOLECULAR BIOLOGY

UNIVERSITY OF RHODE ISLAND
2020

MASTER OF SCIENCE IN CELL AND MOLECULAR BIOLOGY THESIS

OF
JAMIE WANDZILAK

APPROVED:
Thesis Committee:
Major Professor

Kathryn Ramsey
Jodi Camberg
Alison Roberts

Nasser H. Zawia
DEAN OF THE GRADUATE SCHOOL

UNIVERSITY OF RHODE ISLAND
2020

ABSTRACT

Francisella tularensis is a Gram-negative, facultative intracellular bacterial
pathogen and the causative agent of the potentially fatal human disease tularemia
(Sjöstedt, 2007). Like many pathogens, F. tularensis contains a number of proteins
encoded by a variety of genes that are critical to its ability to cause disease including
virulence factors and anti-virulence factors. F. tularensis encodes an anti-virulence factor
called PriM that inhibits replication inside macrophage, one of its key host cell types. The
goal of this study was to elucidate the molecular mechanism for how PriM functions as
anti-virulence factor in F. tularensis subspecies holarctica live vaccine strain (LVS).
Using information about the structure of PriM, we created strains producing mutant PriM
proteins to test the importance of specific structural features to PriM’s function as an antivirulence factor. We also took a genetic approach, initiating study of mutant F. tularensis
cells that re-gained the ability to grow in macrophage despite a genetic background that
should permit PriM production and thereby prevent intramacrophage growth. We found
that a putative binding pocket in PriM may be key to its ability to prevent
intramacrophage growth. We also identified a gene previously unlinked to F. tularensis
virulence whose modification promotes intramacrophage replication and determined that
PriM regulation is more complex than previously appreciated. Continuing our work to
determine how PriM functions as an anti-virulence factor may allow us to identify
bacterially-encoded anti-virulence pathways to exploit in the development of future antimicrobial therapeutics for F. tularensis and potentially other pathogenic organisms.
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CHAPTER 1

INTRODUCTION & REVIEW OF LITERATURE

Francisella tularensis is a Gram-negative, facultative intracellular bacterial
pathogen and the causative agent of the potentially fatal human disease tularemia
(Sjöstedt, 2007). F. tularensis was first identified as an infectious pathogen in 1911 in a
population of ground squirrels in Tulare County, California and was referred to as
Bacterium tularense, named after the county in which it was discovered (McCoy, 1911).
The pathogen was not identified as a human pathogen until 1913 when the bacterium was
isolated from an ocular infection of a butcher (Wherry & Lamb, 1914). Dr. Edward
Francis led much of the early research into this organism, categorizing some of the
clinical manifestations of the disease and giving it the name of tularemia. Later the
pathogen was renamed Francisella tularensis after Dr. Francis (Sjöstedt, 2007). Due to
its highly infectious nature and its ability to be easily aerosolized, F. tularensis is
considered a potential bioweapon (Dennis et al., 2001; Oyston et al., 2004; Sjöstedt,
2007). The United States, Japan, and the Soviet Union conducted research on the
utilization of F. tularensis in biological warfare in the 1950’s and 1960’s (Dennis et al.,
2001). In 1999 F. tularensis was named as a Category A Select Agent by the Centers for
Disease Control and Prevention along with five other pathogens (Rotz et al., 2002).
There are several subspecies of F. tularensis which differ in their ability to cause
disease, all of which are found primarily in the Northern Hemisphere (Sjöstedt, 2007). F.
tularensis subspecies tularensis is highly infectious (as few as 10 organisms can cause
1

disease in humans), has the potential to cause lethal disease, and is only found in North
America (Keim et al., 2007). F. tularensis subspecies holarctica also causes disease in
humans, but has a higher infectious dose and causes a milder form of the disease. An
attenuated form of F. tularensis subspecies holarctica was created as a vaccine strain in
Russia in 1942 (referred to as the live vaccine strain or LVS) by serial passage through
mice and is commonly used as a model in laboratory research because it does not cause
disease in humans but is still lethal in animal models (Sjöstedt, 2007). F. tularensis
subspecies novicida is closely related to F. tularensis, sharing about 97% nucleotide
identity, but despite its lethality in mice it is not known to cause disease in
immunocompetent humans (Sjöstedt, 2007; Kingry & Petersen, 2014). F. novicida has
been found in salt and brackish water, which may serve as an environmental niche, as it
has not been identified in animals or arthropod vectors (Kingry & Petersen, 2014).
Because F. novicida shares a high sequence identity with the more virulent F. tularensis
strains, F. novicida is another commonly used model for the study of tularemia (Kingry
& Petersen, 2014).
F. tularensis has a wide variety of transmission vectors including small mammals,
insects, and can even be water borne. Insect vectors include blood-feeding arthropods
such as ticks, flies, mites, and mosquitoes. These arthropod vectors can spread the
pathogen to small mammals, particularly rabbits, hares, and multiple rodent species
(Keim et al., 2007). Coming into contact with infected animals, such as during hunting or
agricultural activities, allows spread of the disease (Maurin & Gyuranecz, 2016). In some
cases outbreaks have occurred from contaminated water sources that became infected by
animal feces or carcasses (Maurin & Gyuranecz, 2016). In North America, ticks are
2

recognized as an important vector, although the key vector for transmission varies by
geographic region (Keim et al., 2007).
F. tularensis causes tularemia when an infection is established within the host.
Tularemia progresses in different ways depending on the mode of transmission but the
initial symptoms of the disease typically include fever, headache, chills and fatigue. The
ulceroglandular form of the disease is typically caused by infection by arthropod bites,
contact with or ingestion of infected animals, and ingestion of contaminated water
sources (Sjöstedt, 2007). Patients with the ulceroglandular form may develop an ulcer at
the site of infection followed by enlargement of the lymph nodes (Tärnvik & Chu, 2007).
The pneumonic form of the disease is caused by inhalation of aerosolized organisms and
subsequent respiratory infection. This form of the infection, which is also referred to as
the respiratory form, has the potential to be fatal.
The Francisella pathogen is often detected using PCR based assays of clinical
samples taken from the site of infection (Maurin & Gyuranecz, 2016). Once confirmed,
the infection is typically treated using an antibiotic regimen that may include
streptomycin, gentamicin, doxycycline, or ciproflaxine (Dennis et al., 2001). Major
antibiotic resistance among Francisella species has not been observed, but there are
reports of some biovars of subspecies holarctica that are resistant to erythromycin and F.
tularensis is naturally resistant to β-lactam antibiotics (Maurin & Gyuranecz, 2016). Prior
to the antibiotic era, anywhere from 5-60% of cases were fatal, depending on the mode of
transmission (Tärnvik & Chu, 2007). Fatalities from tularemia have decreased with the
use of antibiotic treatments. Currently, the United States has only a few hundred cases per
year, resulting in less than 2% fatality (Sjöstedt, 2007).
3

F. tularensis replication in host cells

As a facultative intracellular pathogen, F. tularensis replicates inside host cells. F.
tularensis can replicate inside a variety of cell types including phagocytes, epithelial
cells, and hepatocytes (Ramond et al., 2012). In particular, macrophage are thought to be
a key niche for F. tularensis replication. Once a bacterial cell is phagocytized by a
macrophage, it must escape the maturing phagosome to avoid being destroyed by the host
cell. While the exact mechanism for phagosomal escape is unknown, it is clear that a
functional Type VI Secretion System is required (Barker et al., 2009; Ledvina et al.,
2018). In order to successfully survive and replicate within host cells, F. tularensis must
adapt to the host environment, prevent recognition by the host immune system, scavenge
nutrients it is incapable of synthesizing, and generate nutrients that are unavailable within
the host (Ramond et al., 2012).

Virulence factors in F. tularensis

The intracellular environment of the host introduces a variety of stressors that F.
tularensis has evolved to overcome. In order to survive within the host cell, F. tularensis
must avoid detection by the host immune system and escape the phagosome, while
surviving acidic environments, host antimicrobials, and amino acid starvation (Jones et
al., 2012). To withstand these stresses and cause disease, pathogens produce virulence
factors, which we define as factors necessary for survival, proliferation, and pathogenesis
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during infection of a host. There have been many genetic screens performed in different
Francisella strains using different model systems to identify putative virulence factors
(reviewed in Meibom & Charbit, 2010; Alkhuder et al., 2010; Ireland et al., 2019;
Ramsey et al., 2020). These screens have identified a number of virulence factors critical
necessary for F. tularensis to survive and replicate within host cells. Some of the more
important classes of virulence factors in F. tularensis are discussed below; however, this
is not an all-inclusive list.

Cell Surface Structures
Some virulence factors involve modifications of the cell surface of the bacteria,
including lipopolysaccharides (LPS) and production of capsule. Capsule is produced to
envelope the LPS and outer membrane of the pathogen and can serve to prevent the
pathogen from being recognized by the host immune system, specifically inhibiting
antibody opsonization and complement-mediated lysis. F. tularensis was found to create
two types of extracellular compounds as part of its capsule, O-antigen (a polysaccharide)
and capsule-like-complexes (a group of glycosylated proteins; CLC) (Freudenberger
Catanzaro & Inzana, 2020). Cells lacking these components experienced growth defects
and are attenuated for virulence in mice (Freudenberger Catanzaro & Inzana, 2020).
Under the capsule, lipopolysaccharides (LPS) makes up the outermost layer of the outer
membrane. LPS is highly immunostimulatory and pathogens often modify their LPS to
avoid immune detection. LPS in F. tularensis has specific structural modifications to
avoid recognition by classical LPS recognition molecules (Rowe & Huntley, 2015).

5

Metabolic Enzymes and Protein Maturation Factors
Once F. tularensis enters the host, it must be able to produce or acquire essential
nutrients. Thus, F. tularensis encodes biosynthesis pathways that are required during host
infection. Among the pathways essential during infection is the purine biosynthesis
pathway, as purines are a limiting metabolite in the host (Pechous et al., 2008; Ramsey et
al., 2020). Cysteine is another limiting nutrient in macrophage during infection. Because
F. tularensis is a cysteine auxotroph, it must obtain this metabolite from the extracellular
environment (Alkhuder et al., 2009). Specifically, F. tularensis utilizes a pathway to
break down host-derived glutathione in the periplasm and imports it into the cytosol to
obtain cysteine (Alkhuder et al., 2009; Ramsey et al., 2020). Mutants that disrupt this
pathway are attenuated for virulence in tissue culture and animal models of infection
(Alkhuder et al., 2009; Ireland et al., 2019; Ramsey et al., 2020).
Some critical virulence factors require modification by protein maturation factors
such as the F. tularensis DsbA homolog, FipB (Qin et al., 2016; Qin et al., 2009;
Straskova et al., 2009; Ren et al., 2014). FipB catalyzes disulfide bond formation and can
refold misfolded proteins, with many of the known substrates being critical virulence
factors (Qin et al., 2016; Schmidt et al., 2013). Because it is necessary for production of
active virulence factors, FipB itself is considered a critical virulence factor (Qin et al.,
2009; Schmidt et al., 2013; Qin et al., 2014; Ren et al., 2014).

The Francisella Pathogenicity Island
F. tularensis subspecies tularensis and holarctica contain two copies of a genetic
island known as the Francisella Pathogenicity Island (FPI), which encodes a type VI
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secretion system subtype 2 (T6SSii; Nano et al., 2004; Russell et al., 2014). Type VI
secretion systems are used to secrete effector molecules into the extracellular
environment or into the membranes of surrounding cells (Bingle et al., 2008). In F.
tularensis, the T6SS secretes effector proteins into the host cell. The F. tularensis T6SS,
and thus the FPI, is absolutely critical for virulence; F. tularensis cannot escape the
phagosome when the T6SS is disabled (Nano et al., 2004). Studies have shown that F.
novicida secretes at least eight proteins through its T6SS, several of which are encoded
outside of the FPI, although few have been well-characterized (Eshraghi et al., 2016;
Ledvina et al., 2018).

Transcription Factors
Several transcription factors are essential for virulence in F. tularensis to control
expression of genes essential for virulence. Possibly the best-studied virulence regulators
specific to F. tularensis are the RNA polymerase-associated transcription factors MglA,
SspA, and PigR (also referred to as FevR in F. novicida), which are key to positively
regulate expression of the FPI (Brotcke et al., 2006; Charity et al., 2007; Brotcke et al.,
2008; Charity et al., 2009; Rohlfing and Dove, 2014; Ramsey et al., 2015; Cuthbert et al.,
2017). MglA and SspA directly interact with RNA polymerase, while PigR interacts with
the MglA-SspA complex and positively regulates those genes which promoters contain a
small sequence motif referred to as the PigR response element (Charity et al., 2007;
Charity et al., 2009; Rolfing et al., 2014; Ramsey et al., 2015; Cuthbert et al., 2017). This
complex of transcription factors has been shown to control expression of about 100
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genes, both within and outside the FPI (Brotcke et al., 2006; Charity et al., 2007; Charity
et al., 2009).
Another transcription factor essential for virulence is the response regulator
PmrA. Cells lacking this transcription factor are not able to replicate in macrophage or
establish an infection in macrophage or animal models and multiple models have been
proposed to explain how PmrA exerts its effects as a positive regulator of virulence
(Mohapatra et al., 2007; Sammons-Jackson et al., 2008; Ramsey & Dove, 2016).

The role of PmrA in regulating gene expression and virulence
PmrA was first investigated in F. novicida due to its high similarity to the PmrA
response regulator in Salmonella, which functions as part of a two component system
(Mohapatra et al., 2007). Two component systems are commonly used in bacteria to
regulate gene expression; E. coli encodes about 30 systems, yet F. tularensis encodes
very few (Yoshida et al., 2015; van Hoek et al., 2019). Two component systems consist
of a sensor kinase that responds to a particular environmental signal by phosphorylating
the DNA-binding transcription factor referred to as the response regulator. The
phosphorylated response regulator then binds DNA to control expression of the genes
important for response to the environmental signal (Stock et al., 2000). PmrA in F.
tularensis is referred to as an orphan response regulator because there is no sensor kinase
encoded nearby, as is typical in two component systems.
In F. novicida, PmrA, also referred to as QseB, controls biofilm formation
(Durham-Colleran et al., 2010). However, the genes encoding the reported biofilm
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formation pathway controlled by QseB are not present in F. tularensis (Durham-Colleran
et al., 2010).
Both F. novicida and F. tularensis LVS cells lacking PmrA are attenuated for
virulence in macrophage and mouse infection models, although how PmrA exerts its
effects to promote virulence has not always been clear (Mohapatra et al., 2007;
Sammons-Jackson et al., 2008; Bell et al., 2009; Ramsey & Dove, 2016). Microarray
analyses of F. novicida cells revealed approximately 60 PmrA-regulated genes, some of
which are encoded on the FPI (Mohapatra et al., 2007). Another study performed in F.
tularensis LVS identified 148 genes controlled by PmrA using microarray analyses.
Similarly to what was found in F. novicida, some genes positively controlled by PmrA
were encoded on the FPI (Sammons-Jackson et al., 2008). Additional experimentation in
F. novicida determined that PmrA can coprecipitate with the transcription factors MglA
and SspA in vitro. These data led to a model proposing that PmrA works together with
MglA and SspA in a complex to control FPI gene expression (Mohapatra et al., 2007;
Bell et al., 2010).
This model, proposing that PmrA works with MglA and SspA to positively
regulate FPI gene expression, has been brought into question by later results. In
particular, a combination of ChIP-Seq and RNA-Seq experiments were used identify the
genetic locations where PmrA is associated and the genes regulated by PmrA in F.
tularensis LVS (Ramsey & Dove, 2016). These studies found very little overlap between
where PmrA associates with DNA compared to where MglA and SspA associate with
DNA. Furthermore, PmrA was not found at FPI promoters or found to control expression
of FPI genes. Instead, PmrA was found to tightly repress expression of a hypothetical
9

gene, which was named priM (PmrA repressed inhibitor of intramacrophage growth)
(Ramsey & Dove, 2016).
It was hypothesized that PmrA is critical for intramacrophage growth because it is
necessary to repress expression of priM (Ramsey & Dove, 2016). To confirm that it is the
presence of priM that is responsible for the attenuation in virulence, cells in which both
pmrA and priM were deleted were tested for their ability to replicate in macrophage.
Consistent with the need for PmrA to repress priM transcription, cells without pmrA and
priM were able to replicate nearly as well as wild-type cells, while deleting priM alone
(i.e., in cells containing PmrA) had no effect on intramacrophage replication (Ramsey &
Dove, 2016). To investigate if repression of priM was necessary to prevent RNA or
protein production, an early stop codon was introduced into priM, to prevent production
of PriM. Cells lacking PmrA with the early stop mutant of priM were also able to
replicate to wild-type levels, indicating that production of PriM prevents intramacrophage
growth in cells lacking PmrA. PriM was also expressed ectopically in wild-type cells
under the control of a promoter not regulated by PmrA and was still found to decrease
intramacrophage replication (Ramsey & Dove, 2016). These results are consistent with
the presence of the PriM protein preventing F. tularensis intramacrophage replication.
These studies led to a new model proposing that the primary function of PmrA is
to repress expression of the novel anti-virulence factor PriM (Ramsey & Dove, 2016).
However, the molecular mechanism that allows PriM to exert its affects as an antivirulence factor is unclear.
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Anti-Virulence Factors
While many studies investigate virulence factors, it is also important to consider
anti-virulence factors to fully understand bacterial pathogenesis (Brown et al., 2016). An
anti-virulence factor functions to decreases or inhibit virulence of a pathogen and have
been discovered in at least 17 bacterial species (Brown et al., 2016). In some cases antivirulence factors play a key role in pathogenesis, but frequently their role is still
incompletely understood. Some anti-virulence factors have been found to regulate
production or release of virulence factors in the context of infection. One example from
Salmonella enterica is the anti-virulence factor CigR. CigR functions by creating a
threshold that the regulatory protein MgtC must overcome in order to become active.
When active, MgtC prevents degradation of PhoP, a master regulator of Salmonella
pathogenesis, and induces cellular changes that lower ATP levels, which effectively
increases tolerance to acid pH and antibiotics (Yeom et al., 2018). Other anti-virulence
factors have been discovered in Mycobacterium tuberculosis and Xylella fastidiosa.
These identified anti-virulence factors are required to prevent hypervirulence, which
could increase detection by the host immune system and be detrimental to continued
disease progression (Ionescu et al., 2013; Shimono et al., 2003).
PriM Functions as an Anti-Virulence Factor
The current model specifies that the major role of PmrA in virulence is to repress
expression of the priM gene; F. tularensis cells lacking PmrA are unable to replicate
inside macrophage due to the production of the anti-virulence factor PriM. Yet little is
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known about this protein, including how PriM functions to prevent intramacrophage
replication is unknown.
PriM has no clear sequence or protein domain homology with other proteins.
However, PriM does contain a canonical N-terminal secretion signal, which can be
readily identified using secretion signal prediction software like SignalIP 5.0
(Armenteros et al., 2019). The PriM secretion signal is likely functional to secrete PriM
through the inner membrane; PriM can be detected in the membrane fraction by western
blotting (Figure 2). PriM does not contain a predicted transmembrane domain, so we
hypothesize that it is found in the periplasm or is further secreted through the outer
membrane.

Figure 1. PriM is found in the membrane fraction. Immunoblot analysis of cytosolic and
membrane fractions comparing VSV-G tagged PriM with wildtype and strains lacking
PriM. Sigma 70 is used as a cytosolic control and LpnA is an abundant membrane protein
in F. tularensis. (Unpublished data, Ramsey & Dove).
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PriM was identified as the most abundant protein associated with outer-membrane
vesicles produced in log-phase F. novicida, though the significance of this is not clear
(McCaig et al., 2013). Another study in F. novicida found that PriM is one of the 95
proteins detected in a secretome analysis, providing further evidence that PriM may be
secreted in F. novicida (Eshraghi et al., 2016). In F. tularensis LVS, PriM was also
identified as being one of 31 proteins that coimmunoprecipitates with MoxR, a protein
that is important for stress response and intramacrophage survival (Dieppedale et al.,
2013). The interaction between MoxR and PriM has not yet been validated and notably,
MoxR is predicted to be cytoplasmic.
Given its key role in virulence and lack of sequence homology to other proteins,
we were interested in obtaining information about PriM’s structure, which might provide
insight into function. Our collaborators used X-ray crystallography to solve a structure of
PriM (Figure 1; Dr. M.A. Schumacher, personal communication). Because the PriM
protein used for crystallography was heterologously produced in E. coli without its
canonical N-terminal secretion signal, the crystalized PriM does not include the first 20
amino acids.

13

Figure 2. Representation of the crystal structure of the PriM protein. This structure has
been described as a novel fold and highlights several key features. The model on the left
displays a surface view with coloration based on the overall charge of each region of the
protein; blue represents an electropositive charge and red represents an electronegative
charge. The model on the right displays a ribbon diagram of the secondary structure with
three overlapping molecules found in three different conformations, each depicted in a
different color (Red, green, and cyan). Not shown in this model is an acetate molecule
that co-crystallized with PriM in region indicated as the small molecule binding pocket.
(Unpublished data, Dr. Maria Schumacher, Duke University Department of
Biochemistry)

The structure of PriM reveals a novel fold with no known structural homology
currently found in the Protein Data Bank. A PriM monomer is approximately 116
angstroms in length, with a long coil-coil domain and flexible, electropositive tip. The tip
region was described as flexible because multiple structures were solved with the tip
region in multiple conformations (Figure 1). Additional features include a disulfide bond
between two cysteines, located near the C-terminus end of the protein, and a bound
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acetate, which co-crystallized with PriM. The bound acetate may indicate the presence of
a binding pocket.
Aims of Study
The mechanism through which PriM exerts its effect as an anti-virulence factor is
still not understood. Using the F. tularensis LVS strain, which is attenuated for virulence
in humans but retains pathogenicity in animal models, we can begin to address this
question using structural and genetic approaches. To identify which structural features are
key to PriM’s anti-virulence function, we engineered mutations targeting specific
structural features. We then assessed the impact of these mutations on the function of
PriM using intramacrophage infection assays. We predicted that mutations in a region of
PriM essential for its function as an anti-virulence factor will allow cells producing the
mutant to replicate in macrophage, in contrast to wild-type PriM, which is inhibitory to
intramacrophage growth.
We have also taken a genetic approach to attempt to identify genes critical for the
function of PriM. In the course of our study we identified a strain that permits
intramacrophage growth despite the absence of PmrA and the presence of priM. We
hypothesized that mutations in this strain interfere with the anti-virulence function of
PriM. Studying the genetic basis for this suppressor strain has increased our knowledge
of F. tularensis virulence and regulation of PriM. Our goal has been to increase our
understanding of bacterially-encoded anti-virulence pathways, which may lead to the
identification of novel targets for anti-microbial therapeutics by exploiting these antivirulence factors to limit bacterial pathogenesis.
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CHAPTER 2

METHODOLOGY

Bacterial Growth Conditions
Francisella tularensis subsp. holarctica LVS was grown at 37 ̊ C aerobically,
shaking in Mueller-Hinton Broth supplemented with 0.025% iron pyrophosphate, 0.1%
glucose, and 2% Isovitalex (S-MHB) or on cystine heart agar plates containing 1%
hemoglobin (CHAH) at 37 ̊ C for 24 hours or until single colonies appeared. When
appropriate, kanamycin was added to the CHAH plates at a concentration of 5 μg/mL.
Escherichia coli strain XL-1 Blue was grown aerobically in lysogeny broth (LB) or on
LB agar plates at 30° or 37 ̊ C, as indicated. When appropriate, kanamycin was added to
the LB or LB agar at a concentration of 50 μg/mL.

Plasmid Design and Construction
Plasmid pKL117 pEX_PriM_mtip2 was created to change the codons in priM
(FTL_0702) specifying amino acids L121-I133, which correspond to the tip region.
Primers containing the modified sequence were used to amplifying flanking regions of
homology of 1000 base pairs on each side of the modified region of priM (FTL_0702).
The DNA included on the primers changed the codons specifying amino acids 121 – 133
from AAA CTT GAA AGT CAA AAG AAA TTA GGC TGG AGA ATT to GGT GGA
16

GGT GGA GGT GGA GGT GGC GGT. The two PCR products containing the modified
region were spliced together using overlap extension PCR, utilizing a 5´ primer including
DNA specifying a BamHI site on its 5´ end and a 3՛ primer including DNA specifying a
KpnI site at its 5՛ end. PCR products and pEX18Kan were digested with BamHI and KpnI
and ligated together to create pKL117.
The plasmid pKR4 pEX_PriM_noC1 was created by amplifying two flanking
regions of homology of about 500 base pairs on each side of the codon specifying
cysteine 303 in priM (FTL_0702) by PCR. Primers included DNA which changed
cysteine 303 to alanine by replacing the codon TTG with TGC, and created an MfeI cut
site. The two PCR products with the modified codon were spliced together using overlap
extension PCR, utilizing a 5´ primer including DNA specifying a BamHI site on its 5´
end and a 3՛ primer including DNA specifying a KpnI site at its 5՛ end. PCR products and
pEX18Kan were digested with BamHI and KpnI and ligated together to create pKR4.
The intermediate plasmid pKL114 modifies the priM codons specifying
tryptophan 219, arginine 222, and tryptophan 226 to encode alanines. To create pKL114,
PCR was used to amplify flanking regions of homology including 800 - 1000 base pairs
on each side of the modified region. The modified region altered DNA specifying amino
acids 219 – 226 from TGG GGT GCA AGA GTA GTT CTT TGG to GCA GGT GCA
GTA GTT CTT GCA. The two PCR products with the modified region were spliced
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together using overlap extension PCR, utilizing a 5´ primer including DNA specifying a
BamHI site on its 5´ end and a 3՛ primer including DNA specifying a KpnI site at its 5՛
end. PCR products and pEX18Kan were digested with BamHI and KpnI and ligated
together to create pKL114. The plasmid pKL115 pEX_PriM_mpk1 was created from
pKL114 and further modifies priM such that the codon specifying tyrosine 270 is
modified to encode alanine. To create pKL115, PCR was used to amplify approximately
600 base pairs flanking the codon specifying tyrosine 270 and using primers modifying
the codon TAT to CGT. The two PCR products with the modified codon were spliced
together using overlap extension PCR, utilizing a 5´ primer including DNA specifying a
BamHI site on its 5´ end and a 3՛ primer including DNA specifying a KpnI site at its 5՛
end. PCR products and pEX18Kan were digested with BamHI and KpnI and ligated
together to create pKL115.
Plasmid pKR58 pEX_FTL_0146_SNP modifies the FLT_0146 codon specifying
phenylalanine 315 to leucine. The plasmid was created by amplifying flanking regions of
homology of 900 – 1000 base pairs on either side of the modified codon by PCR, using
primers that change the codon specifying amino acid 315 from TCC to TAC. The two
PCR products with the modified codon were spliced together using overlap extension
PCR, utilizing a 5´ primer including DNA specifying a BamHI site on its 5´ end and a 3՛
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primer including DNA specifying a KpnI site at its 5՛ end. PCR products and pEX18Kan
were digested with BamHI and KpnI and ligated together to create pKR58.
Plasmid pKL75 pEX_FTL_0702-VSVG was created using the pKL02 vector,
which contains a multiple cloning site including a NotI site and one extra base pair,
which encodes a 3 amino acid alanine linker, followed by DNA specifying the 11 amino
acid vesicular stomatitis virus-glycoprotein (VSV-G) epitope tag, and a stop codon
(Ramsey et al., 2015). DNA specifying the priM gene was amplified from LVS genomic
DNA using a 3´ primer that includes a KpnI site and a 5´ primer with a NotI site. The
pKL02 plasmid and PCR product were digested with KpnI and NotI and the priM
fragment was ligated into the digested pKL02, resulting in pKL75.
Plasmids were transformed into XL-1 Blue chemically competent E. coli and
purified using Qiagen QIAprep Spin Miniprep kits. Plasmid sequences were confirmed
by Sanger sequencing at the URI Genomics and Sequencing Center.

Strain Construction
An allelic exchange protocol was used to create markerless mutations in LVS
essentially as previously described (Maier et al., 2004). Cells were made
electrocompetent by performing 3-5 washes in 10% sucrose. Electroporations using
desired cells and plasmid were performed using the following settings in a 2 mm cuvette:
2.5 kV, 25 μF, and 600 Ω. After electroporation, cells recovered for 4-8 hours shaking
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aerobically in S-MHB. Cells containing a homologous recombination event between the
integration vector and the genomic DNA were selected for by plating transformations on
CHAH plates with kanamycin. Kanamycin-resistant cells were subsequently grown
overnight on CHAH plates without antibiotic, resuspended in 1X PBS, and serial
dilutions were plated onto CHAH plates containing 10% sucrose. Sucrose-resistant
colonies, which should lack the sacB gene encoded on the pEX18Kan plasmid backbone,
were patched on CHAH with and without kanamycin to validate the loss of the
kanamycin resistance gene and plasmid backbone. Colony PCR (and diagnostic digest as
necessary) was used to confirm the presence of the mutation of interest in kanamycin
sensitive cells. Cells with confirmed mutations were purified to single colony and revalidated by PCR and antibiotic sensitivity.
A single integration event was used to add DNA specifying the VSV-G epitope.
Cells were made electrocompetent by performing 3-5 washes in 10% sucrose.
Electroporations using desired cells and plasmid were performed using the following
settings in a 2 mm cuvette: 2.5 kV, 25 μF, and 600 Ω. After electroporation, cells
recovered for 4-8 hours shaking aerobically in S-MHB. Cells containing a homologous
recombination event between the integration vector and the genomic DNA were selected
for by plating transformations on CHAH plates with kanamycin. Kanamycin-resistant
cells were grown overnight on CHAH-Kan plates and assessed by colony PCR for
integration of the desired portion of the plasmid. Strains were validated by isolating
genomic DNA via the MasterPure Complete DNA and RNA Purification Kit (Lucigen)
and the region including the desired mutation was amplified by PCR and sequenced by
Sanger sequencing at the URI Genomics and Sequencing Center.

20

LVS PriM(mtip) and LVS ΔpmrA PriM(mtip) were created using plasmid
pKL117 pEX_PriM_mtip2 and LVS and LVS ∆pmrA cells, respectively. LVS
PriM(C303A) and LVS ΔpmrA PriM(C303A) were created using plasmid pKR4
pEX_PriM_noC1 and LVS and LVS ∆pmrA cells, respectively. LVS PriM(mpk) and
LVS ΔpmrA PriM(mpk) were created using plasmid pKL115 pEX_PriM_mpk1 and LVS
and LVS ∆pmrA cells, respectively. LVS FTL_0146 F315L and LVS ΔpmrA FTL_0146
F315L were created using plasmid pKR58 pEX_FTL_0146_SNP and LVS and LVS
∆pmrA cells, respectively. The plasmid LVS pKL75 pEX_FTL_0702-VSVG was used to
add DNA specifying a VSG-G tag to the priM gene of cells indicated above, producing
LVS ΔpmrA PriM(mtip)-V, LVS ΔpmrA PriM(C303A)-V, and LVS ΔpmrA PriM(mpk)V, as well as to wild-type LVS, producing LVS ΔpmrA PriM-V.

Macrophage Infection Assays
Cells of LVS and derivatives were tested in a macrophage infection assay to
assess their ability to survive and replicate inside macrophage. Throughout the assay,
J774A.1 murine macrophage-like cells were cultured in Dulbecco’s Modified Eagle
Medium supplemented with 10% fetal bovine serum (DMEM-F) grown at 37°C with 5%
CO2. Macrophage were seeded into wells of two 96-well tissue culture-treated plates,
plating approximately 2x104 cells/well. Approximately 16-18 hours after seeding the
macrophage, bacteria were added to wells in triplicate, at a multiplicity of infection
(MOI) of approximately 5. After bacteria were added to the wells, the remainder of the
inoculum was serially diluted in 1X PBS and 10 μL from each dilution was plated onto
CHAH plates in duplicate for enumeration to experimentally determine the MOI for each
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strain. In each 96-well plate, two wells served as controls, ensuring there was no crosscontamination (macrophage only) or survival of extracellular bacteria (bacteria only).
After two hours, the media was removed, the wells were washed twice with sterile 1X
PBS, and DMEM-F with 10 μg/mL gentamicin was added to remove remaining
extracellular bacteria. Two hours after washing, media was removed from the wells of
one plate, wells were washed twice with PBS, and 1% saponin in 1X PBS was added.
Plates were incubated at room temperature for 30 minutes to allow lysis of the
macrophage and 50 μL of the lysate was plated on CHAH plates in duplicate for
enumeration. Twenty-four hours after washing, the remaining 96-well plate was removed
from the incubator and the macrophage were washed and lysed as during the 2-hour
timepoint. The lysates were serially diluted in 1X PBS and 10 μL from each dilution was
plated onto CHAH plates in duplicate for enumeration. The resulting colonies were
counted to assess intramacrophage replication. All intramacrophage growth experiments
were performed at least twice.

Immunoblots
LVS cells and indicated derivatives were grown in 5 mL of S-MHB to mid-log
(OD600 ~0.3-0.4) in biological triplicate. Cells were pelleted by centrifugation and
resuspended in 1X sample loading buffer (NuPAGE) normalized to measured optical
density. Samples were boiled at 98˚C for 10 minutes prior to separation by SDS-PAGE
on NuPAGE 4 to 12% Bis-Tris protein gels (ThermoFisher) with NuPAGE
morpholinoethanesulfonic acid (MES) running buffer (ThermoFisher). Proteins were
transferred to a polyvinylidene difluoride (PVDF) membrane. Membranes were blocked
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with Li-Cor Odyssey Blocking Buffer and washed four times with PBS with NP-40, and
two times with PBS without NP-40. Membranes were incubated with primary antibodies,
either polyclonal rabbit anti-VSV-G (Sigma) or mouse monocolonal anti-LpnA (BEI
Resources, used as a loading control), and then secondary antibodies donkey anti-rabbit
IgG IRDye 800CW and donkey anti-mouse IRDye 680LT. Proteins were visualized using
the Odyssey Infrared Imager at the Rhode Island INBRE Core Facility. All immunoblots
were performed at least twice on biological replicates unless otherwise noted.

RNA Isolation
LVS cells and indicated derivatives were grown in 5 mL of S-MHB to mid-log
(OD600 ~0.3-0.4) in biological triplicate. Cells were pelleted by centrifugation and
resuspended in TRI-Reagent. Samples were incubated at 60°C for 10 minutes and
pelleted by centrifugation at 4°C. Direct-zol RNA isolation kits (ZYMO) were used to
isolate nucleic acids, following manufacturer’s guidelines. Nucleic acids were eluted in
RNase-free molecular grade water and treated with DNaseI for 1 hour at 37°C to degrade
DNA. Samples were re-purified with the Direct-zol RNA isolation kit and RNA samples
were eluted in RNase-free molecular grade water. Purity was assessed by Nanodrop and
gel electrophoresis.

cDNA Synthesis and qRT-PCR
RNA was converted into single-stranded cDNA using the NS5 semi-random
primer (5´-NSNSNSNSNS-3´) and Superscript III Reverse Transcriptase (ThermoFisher).
RNA was removed from cDNA samples by incubation with 1N NaOH (20% final
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concentration) at 65°C, samples were neutralized with 1N HCl (20% final concentration),
and cDNA was purified using the Qiagen QIAquick PCR purification kit. Abundance of
priM transcripts were determined relative to tul4 transcript abundance by quantitative
real-time PCR (qRT- PCR). PowerUp SYBR Green master mix (ThermoFisher) and
primers designed via IDT were used, and samples were run on the Roche LightCycler at
the URI Genomics and Sequencing Center.

gDNA Isolation and Next Generation Sequencing
Total genomic DNA was extracted for use in next-generation sequencing using
the MasterPure Complete DNA and RNA Purification Kit (Lucigen) and following
manufacturer’s instructions. Library preparation and next-generation sequencing was
performed by the Microbial Genome Sequencing Center (University of Pittsburg). Data
was returned as 150 bp paired-end reads with about 8 million reads. Sequencing reads
were aligned to F. tularensis subspecies holarctica LVS reference genome using the
alignment program bowtie2 (Langmead & Salzberg, 2012). Resulting alignments were
outputted as Sequence Alignment Maps or SAM files. The SAM files were converted to
BAM files, the binary version of SAM files, and indexed and sorted using SAMtools (Li
et al., 2009). Variant files were generated using BCFtools to identify differences between
the two alignments. IGV (Robinson et al., 2011) was used to analyze the SAM alignment
files and identify mutations between the two samples.
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CHAPTER 3

FINDINGS

Production of the PriM protein prevents intramacrophage replication in F.
tularensis (Ramsey & Dove, 2016). However, the molecular mechanism underlying the
anti-virulence function of PriM is unknown. To investigate this mechanism, we first
examined the relationship between PriM structure and function. We generated PriM
mutants in regions corresponding to distinct structures (for PriM structure, see Figure 1),
to see if any of these changes disrupt the anti-virulence functions of PriM. (Table 1). One
mutant allowed us to investigate the importance of the charged tip region, as we altered
the charge from electropositive to neutral by replacing all thirteen amino with glycines
[which we refer to as PriM(mtip), Table 1]. In another PriM mutant, we probed the
importance of PriM’s disulfide bond by replacing one of the cysteines, cysteine 303, to
alanine [which we refer to as PriM(C303A), Table 1]. Lastly, we examined the
contribution of the PriM small-molecule binding pocket by altering the charged resides
that line the potential pocket region to alanines [which we refer to as PriM(mpk), Table
1].
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Table 1. PriM mutants investigated in this study
Name

Purpose

Description

PriM(mtip)

Changes the tip
region from an
electropositive
charge to neutral
charge

Mutations in the tip region:
L121-I133 (colored as red
spheres in illustration)
changed to glycines

PriM(C303A)

Removes one of the
two cysteines to
prevent disulfide
bond production

Mutation changing C303 to
alanine (disulfide bond formed
by cysteines 303 and 424 is
colored in yellow in
illustration)

PriM(mpk)

Modifies “pocket”
region, which
potentially binds
small molecules

Mutations in the small
molecule binding pocket
region: R222, W219, W226,
and Y270 (colored in red in
illustration; acetate molecule
in the potential binding pocket
is colored in blue) changed to
alanine.

Illustration

We modified priM to encode each mutant in wild-type cells as well as in cells that
lack the repressor PmrA. In wild-type cells, the transcription factor PmrA represses
expression of priM, such that not enough PriM is produced to influence intramacrophage
growth (Ramsey & Dove, 2016). Thus, PriM mutations in the wild-type background
should not affect virulence and serves as a control of any unexpected changes in gene
expression caused by the modifications made in priM. In the background that lacks
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PmrA, priM is no longer being repressed and we can assess the anti-virulence function of
the PriM protein and mutants.
To test the significance of each structural region of PriM on its function as an
anti-virulence factor, we examined the ability of cells with PriM mutants to replicate
inside a murine macrophage-like cell line, J774A.1 cells. These results allow us to assess
the significance of each structural element to the anti-virulence function of PriM.
Specifically, cells that produce PriM (i.e., cells lacking pmrA) are unable to replicate in
macrophage. Therefore, if cells producing the mutant PriM proteins are able to replicate
in macrophage at or near wild-type levels, it would suggest that the modified structural
region is essential for the anti-virulence function of PriM.

Changes in the tip region do not affect PriM’s anti-virulence function
Using the PriM(mtip) mutant (Table 1), we tested the contribution of the
electropositive charge of the PriM tip region to its function as an anti-virulence factor in
the context of intramacrophage growth. When performing intramacrophage growth
assays, we include several controls. Wild-type LVS cells are able to survive and replicate
during the 24-hour infection. Cells lacking PmrA (which containing a wild-type PriM;
∆pmrA) do not replicate well in macrophage (Mohapatra et al., 2007). We compare the
intramacrophage growth phenotype of two test strains to these controls. The first test
strain is the PriM mutation in the wild-type background [WT PriM(mtip)]; we expect that
the presence of PmrA will repress mutant PriM production, allowing wild-type levels of
intramacrophage replication. The second strain tested is the PriM mutation in the ΔpmrA
background [∆pmrA PriM(mtip)]; the absence of PmrA will allow production of the
mutant PriM. We compare the ability of cells producing the mutant PriM to the cells with
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wild-type PriM (∆pmrA) to replicate within macrophage to determine the effect the
mutant PriM has on virulence. We found that the PriM(mtip) mutant cells are not able to
regain the ability to replicate to wildtype levels inside macrophage cells (Figure 3). These
results demonstrate that PriM is still able to function as an anti-virulence factor if the
charge of the tip region is modified from electropositive to neutral. This suggests that the
electropositive charge of the tip region of PriM is not required for its anti-virulence
function.

Figure 3. Intramacrophage growth assay testing PriM(mtip) mutants. Survival of wildtype F. tularensis LVS or indicated mutants 24 hours after infection of macrophage. Data
represents the number of bacteria recovered after 24 hours of intracellular growth.
Significance of p ≤ 0.01 is indicated by a (*) between bars where a 2-tailed t test was
performed and otherwise was labeled as not significant (ns). Error bars represent standard
deviation. Assays were performed in duplicate with representative data shown.
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Loss of the disulfide bond does not affect PriM function
Periplasmic disulfide bond formation is key for maturation of critical F. tularensis
virulence factors. Disulfide bond formation is catalyzed by the enzyme FipB, the F.
tularensis DsbA homolog (Qin et al., 2016). PriM is also a substrate of FipB (Qin et al.,
2016), which is consistent with our finding that PriM contains a single disulfide bond
(Figure 1, Table 1). We hypothesized that the production of PriM prevents virulence
because high levels of PriM may titrate FipB away from critical virulence factors,
preventing virulence factor maturation. Without functional virulence factors, the PriMproducing bacterial cells would no longer be able to replicate in macrophage. To test this
hypothesis, we assessed cells producing a PriM variant that is unable to create an
intramolecular disulfide bond. Specifically, these cells lack PmrA and contain PriM with
the mutation C303A, changing one of the two cysteines in PriM to an alanine [∆pmrA
PriM(C303A)]. We found that cells producing PriM with the C303A mutation were still
unable to replicate to wildtype levels inside macrophage cells (Figure 4). These results
suggest that PriM does not function as an anti-virulence factor by titrating FipB activity
away from critical virulence factors.
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Figure 4. Intramacrophage growth assay testing the PriM(C303A) mutants. Survival of
wild-type LVS or indicated F. tularensis mutant cells 24 hours after infection of
macrophage. Data represents the number of bacteria recovered after 24 hours of
intracellular growth. Significance of p ≤ 0.05 is indicated by a (*) between bars where a
2-tailed t test was performed and otherwise was labeled as not significant (ns). Error bars
represent standard deviation. Assays were performed in duplicate with representative data
shown.
Disrupting the small molecule binding pocket inhibits PriM’s anti-virulence
function
Finally, we assessed the contribution of the potential small molecule binding
pocket to PriM’s anti-virulence activity. We tested the ability of cells producing PriM
with mutations in residues key to forming the potential small molecule binding pocket
[∆pmrA PriM(mpk)] to replicate in macrophage. We found that F. tularensis cells
producing PriM(mpk) are able to replicate to levels closer to wildtype inside macrophage
(Figure 5). These results are consistent with the small molecule binding pocket being
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involved in PriM’s anti-virulence function. Yet it is also possible that the disruption of
the potential binding pocket could also affect proper folding, localization, or abundance
of PriM and thus prevent its anti-virulence function indirectly; we next sought to address
this concern.

Figure 5. Intramacrophage growth assay testing PriM(mpk) mutants. Survival of wildtype LVS or indicated F. tularensis mutant cells 24 hours after infection of macrophage.
Data represents the number of bacteria recovered after 24 hours of intracellular growth.
Significance of p ≤ 0.05 is indicated by a (*) between bars where a 2-tailed t test was
performed and otherwise was labeled as not significant (ns). Error bars represent standard
deviation. Assays were performed in duplicate with representative data shown.

Addition of a VSV-G epitope tag does not affect PriM function
Having determined how mutations in key structures of PriM influence
intramacrophage growth, we needed to ascertain if our results are due to changes in
specific structures or overall destabilization of the PriM protein. As there is no
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commercial antibody for PriM, we used an epitope-tagging approach. Because the Cterminal region of PriM was found to be solvent-exposed in the PriM crystal and the Nterminus of PriM encodes a Sec secretion signal, we modified the priM gene to encode a
C-terminal vesicular stomatitis virus-glycoprotein (VSV-G) tag. Given that the VSV-G
tag is small, only 11 amino acids in size, we reasoned that when added to the unstructured
C-terminal region it would be unlikely to interfere with PriM function. We then assessed
the effect of the epitope tag on the anti-virulence function of PriM by testing cells
producing PriM with a C-terminal VSV-G tag (∆pmrA PriM-V) in an intramacrophage
growth assay. We determined that addition of the C-terminal VSV-G tag does not affect
the anti-virulence function of PriM (Figure 6).
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Figure 6. Intramacrophage growth assay testing PriM-VSV-G mutant. Survival of wildtype LVS or indicated F. tularensis mutant cells 24 hours after infection of macrophage.
Strain referred to as ΔpmrA PriM-V specifies a C-terminal VSV-G tag. . Data represents
the number of bacteria recovered after 24 hours of intracellular growth. Significance of p
≤ 0.05 is indicated by a (*) between bars where a 2-tailed t test was performed and
otherwise was labeled as not significant (ns). Error bars represent standard deviation.
Assays were performed in duplicate with representative data shown.

PriM mutant proteins are produced
Having confirmed that the addition of a VSV-G tag to PriM has no apparent effect
on its function, we modified strains to produce epitope-tagged versions of PriM mutants.
Using whole-cell lysates, we used immunoblotting to quantify the abundance of each
PriM-V variant in comparison to the wild-type PriM-V in ∆pmrA cells, using an antibody
to the F. tularensis lipoprotein LpnA as a loading control (PmrA does not control
expression of LpnA [Ramsey and Dove 2016]; Figure 7). Because wild-type PriM is
extremely abundant in ∆pmrA cells, the PriM-V samples were diluted fifty-fold relative
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to other samples to prevent signal saturation. We are able to detect all of the PriM
mutants, although they were all less abundant than wild-type PriM. We detected the least
amount of PriM in the ΔpmrA PriM(mtip)-V cells. Given that ∆pmrA PriM(mtip) cells
still retain PriM’s anti-virulence function, our results suggest that the amount of PriM
necessary to exert its function as an anti-virulence factor is much lower than the amount
present in the ∆pmrA strain and can be as low as the amount of PriM present in the
∆pmrA PriM(mtip) cells. There is still more PriM present in the ∆pmrA PriM(mpk)-V
cells than in ∆pmrA PriM(mtip)-V cells, suggesting that the increase in virulence in cells
with PriM(mpk) is not due to lack of protein (Figure 7). However, it is important to note
that the majority of PriM produced in the ∆pmrA PriM(mpk)-V cells appears to have a
shift in mobility.

Figure 7. Relative abundance of wild-type and mutant PriM proteins. The abundance of
specified PriM proteins present in whole-cell lysates was determined by immunoblot
using an anti-VSV-G antibody. The LpnA protein, detected with an anti-LpnA antibody,
serves as a loading control. Note that the LVS ΔpmrA PriM-V strain was diluted 50-fold
to prevent signal saturation. Triplicate biological samples from a representative
experiment are shown.
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Cells lacking pmrA with restoration of virulence: investigating a suppressor mutant

To study the role of PriM, we utilize cells that lack pmrA, the repressor that
prevents PriM production. Unexpectedly, we identified cells that lack pmrA (and contain
priM), that are as virulent as wildtype cells (Figure 8). We refer to these cells as the
PmrA suppressor strain [∆pmrA(sup)] because PmrA is no longer essential for
intramacrophage survival of these cells.

Figure 8. Intramacrophage growth assay testing ΔpmrA suppressor mutant. Survival of
wild-type LVS or indicated F. tularensis mutant cells 24 hours after infection of
macrophage. Assays were performed in duplicate with representative data shown. Data
represents the fold change from 2 hours to 24 hours with error bars representing standard
deviation. Significance of p ≤ 0.01 is indicated by a (*) between bars where a 2-tailed t
test was performed and otherwise was labeled as not significant (ns). Statistical tests were
performed on data representing cells recovered after 24 hours of infection. Error bars
represent standard deviation.
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Since there is a difference in the intramacrophage growth phenotype between the
ΔpmrA strain and the ΔpmrA suppressor cells, we reasoned that there must be some
genetic difference between the two strains. After verifying by Sanger sequencing that
pmrA is absent and priM is identical in both strains, we hypothesized that there must be
other mutations somewhere in the ∆pmrA suppressor genome that results in this
phenotypic change. We used whole-genome resequencing to test this hypothesis. After
isolating genomic DNA (gDNA) from wild-type, ∆pmrA, and ∆pmrA(sup) cells, we sent
the gDNA to the Microbial Genome Sequencing Center (University of Pittsburg) for next
generation library preparation and sequencing. We aligned the resulting sequencing data
to the reference F. tularensis LVS genome to identify polymorphisms between the
sequences of the three strains and the reference sequence.
Our results identified three single nucleotide polymorphisms (SNPs) present only
in the ∆pmrA suppressor genome (Table 2). One mutation is in FTL_0146, which is
annotated as an ATP binding protein. This mutation changed an C to A, a
nonsynonymous mutation changing a phenylalanine to a leucine at amino acid 315 in
FTL_0146. Another mutation is present in FTL_1339, which is annotated as a protondependent oligopeptide transport. This second mutation changed a C to an A, but it is a
synonymous mutation and the encoded amino acid remains a glycine. The last mutation
was found in a non-coding region upstream of FTL_0869 (annotated as a hypothetical
protein) that changes a G to a T.
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Table 2. Mutations unique to PmrA suppressor cells
Mutation Type

Gene or Region

Locus Number

Mutations

FTL_0146

Nucleotide
Change
C152592A

SNP

ATP Binding Protein

SNP

Proton-dependent
oligopeptide
transport

FTL_1339

C1274708A

G421G

SNP

Upstream of
hypothetical protein

Upstream of
FTL_0869

G849877T

N/A

F315L

Mutation of an ATP binding protein increases virulence of cells producing PriM
Because it is the single polymorphism present in only the ∆pmrA suppressor cells
that alters a protein, we hypothesized that the change in FTL_0146 may allow cells
lacking pmrA to replicate in macrophage. FTL_0146 encodes an ATP binding protein
that is typically found as part of an ATP-Binding Cassette (ABC) transport system
(Atkins et al., 2006). ABC transport systems are common in bacteria and are used for the
import and export of a wide variety of molecules, including; amino acids, short peptides,
ions, iron complexes, metals, mono- and oligo- saccharides (Saurin & Dassa, 1994).
These systems typically consist of three parts: a transmembrane component, an ATP
binding component and a substrate binding protein (Figure 9A; Atkins et al., 2006). The
protein encoded by FTL_0146 is predicted to have two domains. One domain is predicted
to bind ATP (amino acids 26-136) and the other is frequently found associated with
proteins with ATPase domains (C-terminal AAA-associated domain, amino acids 301419). To the best of our knowledge, the function of the C-terminal AAA-associated
domain, which includes the amino acid altered by the mutation identified in ∆pmrA
suppressor cells, is unknown (Figure 9B). This gene has not previously been identified as
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being important for intramacrophage growth, but its ATP binding domain and the
upstream ABC transporter membrane protein (FTL_0145) are essential for in vitro
growth (Ramsey et al., 2020).

Figure 9. ABC transport systems and an ATP-binding protein from F. tularensis. A.
Typical example of the process of an ABC transport system. Figure from Bruslind,
General Microbiology. B. Predicted protein domains of the ABC transport protein
encoded by FTL_0146. The location of the mutation is indicated by the blue arrow.
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To evaluate the contribution of the mutation in FTL_0146 to intramacrophage
growth, we recreated the F315L mutation in FTL_0146 in wildtype and ∆pmrA cells and
tested the ability of the resulting cells [WT FTL_0146(F315L) and ∆pmrA
FTL_0146(F315L)] to grow in intramacrophage growth assays. We found that the
FTL_0146(F315L) mutation increases the ability of cells lacking pmrA to replicate in
macrophage cells, although not quite to wild-type or ∆pmrA suppressor levels (Figure
10). It is possible that the ability of the ∆pmrA suppressor cells to replicate to wild-type
levels in macrophage is due to a combination of the mutation in FTL_0146 and one or
both of the other identified mutations. It is notable that the FTL_0146(F315L) mutation
results in increased intramacrophage growth when present in wild-type cells. It seems
that the FTL_0146(F315L) mutation contributes an intramacrophage growth advantage to
the ∆pmrA suppressor cells but this advantage may not be specific to cells that lack pmrA.
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Figure 10. Intramacrophage growth assay testing FTL_0146(F315L) mutants. Survival
of wild-type LVS or indicated F. tularensis mutant cells 24 hours after infection of
macrophage. Data represents the number of bacteria recovered after 24 hours of
intracellular growth. Significance of p ≤ 0.05 is indicated by a (*) between bars where a
2-tailed t test was performed and otherwise was labeled as not significant (ns). Error bars
represent standard deviation. Assays were performed in duplicate with representative data
shown.

Transcript abundance of priM is decreased in suppressor mutant strain
Having determined that the intramacrophage growth phenotype of ∆pmrA
suppressor cells may be the result of multiple mutations, we sought to understand the
molecular mechanism that allows the ∆pmrA suppressor cells to grow in macrophage. A
simple reason for the increased ability of the ∆pmrA suppressor cells to grow in
macrophage could be that they produce less PriM. To explore this possibility, we
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examined priM transcript levels in ∆pmrA suppressor cells compared with ΔpmrA cells.
Specifically, we used qRT-PCR to assess priM transcript abundance in LVS, ΔpmrA, and
ΔpmrA suppressor cells. Consistent with previous reports, we found that ∆pmrA cells
have a 300-fold increase in priM transcript abundance compared to wild-type cells
(Ramsey & Dove, 2016). Our comparison of priM transcript abundance in the ΔpmrA
suppressor cells revealed that they have about 7 times less priM transcript than the
ΔpmrA cells and only about 40-fold more priM transcript than wild-type cells

Figure 11. Quantification of priM transcript abundance in wildtype and indicated mutant
strains by quantitative RT-PCR (qRT-PCR). Transcripts were normalized to tul4, whose
expression is not influenced by PmrA, with wildtype (LVS) set to a value of 1. Error bars
represent one standard deviation from the value, calculated using the mean threshold
value. Significance of p ≤ 0.05 is indicated by a (*) between bars where a 2-tailed T-test
was performed and otherwise was labeled as not significant (ns). Data are displayed on a
logarithmic scale. Experiments were performed in duplicate using triplicate biological
samples; a representative data set is shown.
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Protein abundance of PriM is decreased in suppressor mutant strain
After determining that levels of priM transcript are decreased in the ΔpmrA
suppressor, we wanted to assess the impact of this lowered transcript abundance on
abundance of the PriM protein. Similarly to the experiments with the PriM mutants
described above, we added DNA specifying the VSV-G epitope tag to the 5´ end of the
priM gene in the ∆pmrA(sup) cells. Because PriM is extremely abundant in ∆pmrA cells,
we diluted ∆pmrA PriM-V lysates fifty-fold relative to other samples to prevent signal
saturation; ∆pmrA(sup) PriM-V lysates were not diluted. We found that PriM is in fact
less abundant in the ΔpmrA suppressor strain than in wild-type cells lacking pmrA
(Figure 12). This decrease in PriM protein abundance may completely or partially explain
the ability of the ΔpmrA suppressor strain to replicate in macrophage to levels similar to
wild-type.
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Figure 12. Relative abundance of PriM in ∆pmrA and ∆pmrA suppressor cells. The
abundance of specified PriM proteins present in whole-cell lysates was determined by
immunoblot using an anti-VSV-G antibody. The LpnA protein, detected with an antiLpnA antibody, serves as a loading control. The LVS ΔpmrA PriM-V strain was diluted
50-fold. Duplicate samples are shown. Data shown is from a single experiment.
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CHAPTER 4

DISCUSSION

Summary
Francisella tularensis is a highly infectious bacterial pathogen that has been
classified as a potential bioweapon. Like many other bacterial pathogens, F. tularensis
encodes an uncharacterized ani-virulence factor. Anti-virulence factors provide a unique
target for anti-microbial research, as we may be able to exploit these systems to reduce or
halt the virulence programs of pathogens. In understanding the role of this anti-virulence
factor in F. tularensis we can further our knowledge of virulence regulation in this
pathogen, which may apply to other pathogens as well.
While the presence of the novel F. tularensis anti-virulence factor PriM prevents
intramacrophage replication, the exact molecular mechanism that results in this
attenuation of virulence is unknown. Because the structure of the protein has been solved,
we have been able to investigate specific structural elements that might provide insight
into how PriM functions. We also took a genetic approach, investigating mutant cells that
allow intramacrophage growth despite the presence of PriM, which we hypothesized
contained mutations suppressing PriM’s anti-virulence function. Our work led us to
discover that the pocket region of PriM is important for its function as an anti-virulence
factor, that there are additional levels of regulation of priM, and that modification of a
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gene previously unknown to play a role in virulence allows for increased
intramacrophage growth.

Results of PriM structure function analyses
In collaboration with the protein structure experts who solved the PriM structure,
we identified elements of the PriM structure that we hypothesized may be key to its
function as an anti-virulence factor. In particular, we identified the electropositive “tip”
region, a putative small molecule binding pocket, and a disulfide bond as structural
elements which might be key to PriM’s function. After studying mutations in these key
features in PriM, we were able to conclude that the charged tip region of the protein and
the disulfide bond are likely not essential for PriM to function as an anti-virulence factor.
Modification of the potential small molecule binding pocket of PriM resulted in a partial
restoration of intramacrophage replication, suggesting that this region is important for
PriM as an anti-virulence factor. Although we found that the modified PriM proteins are
less abundant than unmodified PriM, our results are consistent with changes in
intramacrophage growth phenotypes due to specific modifications rather than loss of
PriM (Figure 7).
The tip region of PriM was chosen as potentially being important for antivirulence because it has an overall electropositive charge. This charged region could be
important for an interaction with another protein or complex that aids in causing antivirulence. Interaction sites in protein-protein interactions can rely on specific electrostatic
charges and altering these charges can weaken or prevent these interactions (Reichmann
et al., 2007). However, after testing a mutant that altered the tip region of PriM to a
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neutral charge, we found no increase in intramacrophage replication, meaning that PriM
was still able to function as anti-virulence factor (Figure 3). These results suggest that an
electropositively-charged tip region of PriM is not essential for a protein-protein
interaction that leads to attenuated intramacrophage replication. While verifying
production of the PriM tip region mutant, we noticed a decrease in the abundance of PriM
as compared to wild-type PriM (Figure 7). This trend was observed for each of the PriM
mutants, but the tip region mutant is the least abundant PriM mutant. One explanation for
the decrease in PriM abundance in the tip mutant could be that there is decreased
translation of the priM tip mutant mRNA due to ribosome stalling. To create the tip
region mutant, we changed 13 amino acids all glycines, resulting in a 14 amino acid
stretch of glycines (Table 1). Ribosome stalling can occur when the ribosome encounters
a region with the same amino acid many times in a row, due to needing the same tRNA,
which can slow down the rate of translation and decrease the abundance of the protein
(Buskirk & Green, 2017). Although three distinct codons were used to code the stretch of
14 glycines and F. tularensis LVS encodes three tRNAs for glycine, it is possible that the
high demand for glycine-containing tRNAs might cause ribosome stalling. Alternately,
the amino acid changes made in the PriM mutants may have decreased the stability of the
protein, leading to overall less abundant PriM.
Cells producing PriM (i.e., cells lacking the repressor PmrA) produce high levels
of PriM. Because PriM contains an intramolecular disulfide bond, we hypothesized that
PriM may function by titrating the enzyme responsible for disulfide bond creation, FipB,
away from critical virulence factors that contain disulfide bonds; FipB activity is known
to be essential for F. tularensis virulence (Qin et al., 2016). We altered one of PriM’s two
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cysteines to an alanine, preventing the formation of intramolecular disulfide bonds (Table
1). After testing this PriM variant in intramacrophage growth assays, we did not find any
recovery in intramacrophage growth, suggesting that the presence of a disulfide bond in
PriM is not essential for its anti-virulence function and PriM does not function by
titrating disulfide bond formation activity away from virulence factors (Figure 4). One
caveat is that the mutation made in PriM targeted the formation of intramolecular
disulfide bonds; it does not exclude the possibility that intermolecular disulfide bonds
could be formed. Specifically, each modified PriM molecule still contains one of its two
cysteines available for disulfide bond formation and it is possible that a disulfide bond
would form between cysteines of two separate PriM molecules. We raise this possibility
because in our immunoblots detecting mutant PriM-V (Figure 7), a band that may
correspond to dimerization between PriM molecules is evident in lanes with lysates from
the ∆pmrA PriM(C303A)-V cells (Figure 7). PriM(C303A)-V is expected to have a
molecular mass of 56 kDa and the most intense signal corresponds to a band of that size.
A dimer of PriM(C303A)-V would have a molecular mass of 112 kDa and we detect a
fainter band corresponding to that molecular weight (Figure 7). Furthermore, this higher
molecular weight band is not detected in any other lysate samples, suggesting it is
specific to lysates containing PriM(C303A)-V. Due to the possibility of intermolecular
disulfide bond formation, we cannot completely exclude our hypothesis that PriM
functions by titrating away disulfide bond formation activity from other virulence factors.
The final PriM mutant examined the contribution of the potential small molecule
binding pocket to PriM’s anti-virulence function. Testing this PriM mutant in
macrophage lead to a partial recovery of intramacrophage growth (Figure 5). Although
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ΔpmrA PriM(mpk) cells do not replicate to the same level as wild-type cells in
macrophage, they replicate nearly 15-fold more than cells producing wild-type PriM
(ΔpmrA cells). These results are consistent with the idea that the changes made to the
potential small molecule binding pocket in PriM are affecting its anti-virulence function.
One important note to make is that we have been referring to the pocket region of PriM
as a potential small molecule binding pocket because a small molecule, acetate, cocrystallized in this location. However, it also possible that this so-called pocket region is
an interaction site for a protein-protein interaction. Additionally, in verifying production
of the mutant versions of PriM, we noticed that the majority of the signal corresponding
to the PriM(mpk) mutant migrates about a 3 kDa lower when compared to wild-type and
other PriM mutants (Figure 7). There are multiple explanations that could account for this
apparent change in molecular weight. One is that there is a molecule complexed with
PriM in the pocket region that can no longer bind the PriM(mpk) mutant, although this
interaction would have to be strong enough to withstand the denaturing and reducing
environment of SDS-PAGE. Another possibility is that the mutations that we made in this
particular mutant caused mis-folding or mis-localization of the PriM protein, and a
portion of the protein is degraded (Too et al., 2013).

Characterizing cells that grow in macrophage despite loss of PmrA
Previous work determined that PmrA is essential for intramacrophage growth
because it is necessary to repress production of priM (Ramsey et al., 2016). During the
course of these studies, we identified cells that lack the repressor PmrA and contain priM
yet replicate to wildtype levels in macrophage (Figure 8). We refer to these cells as the
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ΔpmrA suppressor strain because the intramacrophage growth defect of cells lacking
PmrA is suppressed. We hypothesized that these cells regained their ability to replicate in
macrophage due to a mutation in a potential PriM interaction partner essential for PriM’s
an anti-virulence effects. Whole genome re-sequencing of wild-type, ∆pmrA and the
∆pmrA suppressor cells identified three single nucleotide polymorphisms unique to the
∆pmrA suppressor cells (Table 2). As there was only a single mutation predicted to result
in a change at the protein level, we considered it the most likely mutation to cause the
observed phenotypic change. This mutation changes the phenylalanine at position 315 to
leucine in the protein encoded by locus FTL_0146.
We tested the contribution of the FTL_0146 F315L mutation to suppression of the
∆pmrA intramacrophage growth phenotype by re-creating the mutation in both wildtype
and ΔpmrA cells. Cells lacking PmrA with the single FTL_0146 mutation [∆pmrA
FTL_0146(F315L)] had an increased ability to replicate in macrophage compared to cells
lacking PmrA (more than 50-fold) but did not replicate as well as either wild-type cells or
the ∆pmrA suppressor cells (Figure 10). Additionally, we found that the
FTL_0146(F315L) mutation increased intramacrophage replication in not only the cells
lacking PmrA, but also when present in wild-type cells (Figure 10). These results suggest
that other mutations in the ∆pmrA suppressor strain contribute to the restoration of
intramacrophage growth and that the mutation in FTL_0146 results in better
intramacrophage replication overall, irrespective of the presence of PmrA.
The protein encoded by FTL_0146 is an ATP binding protein predicted to
function as a component of an ATP-binding cassette (ABC) transport system. ABC
transport systems are found in eukaryotes, archaea, and bacteria and are common in
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bacteria for both import and export of a variety of molecules (Saurin & Dassa, 1994). In
F. tularensis subspecies tularensis, approximately 15 functional ABC transport systems
have been identified (Atkins et al., 2006). The homolog of FTL_0146 in subspecies
tularensis (FTT_0266) was predicted to be involved in nitrate transport but was also
identified as being part of a nonfunctional ABC transport system (Atkins et al., 2006).
However, results from a transposon insertion sequencing (Tn-Seq) experiment identified
FTL_0145, the predicted inner membrane transport protein associated with FTL_0146,
and the ATP binding domain of FTL_0146 as essential for in vitro growth, suggesting
that this system may be functional in LVS (Ramsey et al., 2020). In addition to its ATP
binding domain, FTL_0146 is predicted to have a C-terminal AAA-associated domain,
the function of which is unknown. The mutation in FTL_0146 that permits increased
intramacrophage growth occurs in this C-terminal AAA-associated domain (Figure 9). It
is possible that the mutation in FTL_0146 provides an intramacrophage growth benefit by
altering the function of the transport system. This could either directly improve
intramacrophage growth or the modified function could decrease PriM production and
indirectly improve intramacrophage growth.
Because it seems that multiple mutations influence the ability of the ∆pmrA
suppressor strain to replicate in macrophage, we sought to further understand the
molecular mechanism that permits intramacrophage growth of the ∆pmrA suppressor
cells despite the presence of priM. We reasoned that the enhanced intramacrophage
growth of these cells could be due to either a change in a pathway or interaction partner
necessary for PriM function, rendering PriM ineffective at functioning as an antivirulence factor, or a change in the amount of PriM produced. To assess the latter
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possibility, we examined PriM transcript and protein abundance in the ∆pmrA suppressor
cells. We found that although there is still more priM transcript in the ∆pmrA suppressor
strain compared to wild-type, there is significantly less priM transcript than in the ΔpmrA
strain (almost 10-fold; Figure 11). We next sought to confirm that the lower priM
transcript abundance in ∆pmrA suppressor cells results in less PriM at the protein level.
Preliminary immunoblot analysis confirmed that there is less PriM protein present in the
ΔpmrA suppressor strain, is consistent with the observed lower priM transcript abundance
(Figure 12). We have not yet determined if the observed decrease in PriM protein is
sufficient to permit the increased intramacrophage growth observed in the ΔpmrA
suppressor mutant. It is possible that the lower PriM abundance combined with the
intramacrophage growth benefit provided by the FTL_0146 mutation could account for
the large increase in intramacrophage growth observed by the ΔpmrA suppressor mutant.
At this point we do not know why the levels of priM transcription are lower in the ΔpmrA
suppressor, but it does indicate that priM regulation may be more complex than
previously appreciated; it seems there are other factors that can control production of
priM other than PmrA.

Future Experiments
Although we have made significant progress towards understanding PriM, many
questions remain regarding the function of this anti-virulence factor. Here we will
propose a number of experiments to answer some of the original questions we had as well
as some new questions that surfaced during the course of this study.
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Does PriM prevent disulfide bond formation in virulence factors?
We had hypothesized that PriM functions as an anti-virulence factor by
preventing maturation of virulence factors, monopolizing the activity of the enzyme
responsible for disulfide bond formation. We tested this hypothesis by creating a mutant
that is unable to form an intramolecular disulfide bond [PriM(C303A)]. This PriM mutant
would, in principle, not interact with FipB, the enzyme necessary for disulfide bond
formation. However, immunoblot analyses suggest that the PriM(C303A) mutant is
capable of forming intermolecular disulfide bonds. Thus, the PriM(C303A) mutant may
still be interacting with FipB and potentially preventing FipB interaction with virulence
factors. To address this possibility, we will create a mutant that replaces both cysteines
with serines (serine is more structurally similar to cysteine than alanine) to prevent
formation of both intramolecular and intermolecular disulfide bonds. By testing this
mutant in intramacrophage growth assays we will be able to come to a more conclusive
answer about the role of disulfide bond formation in PriM’s function as an anti-virulence
factor.

What proteins interact with PriM?
During the course of this study we were unable to identify any PriM interaction
partners, but we did identify a region of PriM that is necessary for virulence. The mutant
that we used to discover this region could provide an important tool for identifying
potential interactions in that region. We would like to take a biochemical approach to
address this question and immunoprecipitate direct interaction partners of PriM and
PriM(mpk). If we find proteins that IP with PriM and not the pocket mutant, they would

52

be candidates for interaction partners that are important for anti-virulence. One reason
this experiment may cause some difficulties is that PriM is found in the membrane
fraction of the cell and must be immunoprecipitated from that fraction, which is
insoluble, however this type of experiment has been successfully performed (Srivastava
et al., 2017).

How do the mutations in the ∆pmrA suppressor strain allow replication in macrophage?
We observed a decrease in PriM transcript abundance in the ΔpmrA suppressor
strain but have not yet identified what is causing this decrease. One way to answer this
question is to examine the levels of PriM transcript in the ΔpmrA FTL_0146(F315L)
mutant to determine if the mutation in FTL_0146 plays a role in decreasing the amount of
PriM being produced, or if another change in the ΔpmrA suppressor strain causes this
decrease. Furthermore, it is still not clear which mutations in the ΔpmrA suppressor strain
are responsible for the increase in intramacrophage growth. After recreating the
FTL_0146 mutation in cells lacking PmrA, we found increased intramacrophage growth,
but the increase did not reach the level of the ΔpmrA suppressor strain. To examine the
role of the other identified mutations in the ∆pmrA suppressor strain, we will recreate the
other two mutations identified in the ΔpmrA suppressor and test their contribution to
increased survival in intramacrophage growth assays.
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Can we identify direct interaction partners or pathways important for PriM function
genetically?
One of our goals was to identify genes important for PriM to function as an antivirulence factor. Originally we planned to take a genetic approach, creating a strain with
an extra copy of priM, mutagenize this strain with a transposon, and identifying mutants
able to replicate in macrophage, presumably due to inactivation of a PriM interaction
partner. This approach requires starting with cells containing an extra copy of priM, as
otherwise the majority of recovered mutants would contain a transposon insertion in
priM. Unfortunately, we were unable to create the strain with two copies of priM. Given
these technical difficulties, we will take an alternate approach, performing Tn-Seq on the
ΔpmrA cells grown in vitro in comparison with those grown in macrophage, analogous to
a recently-published experiment (Ramsey et al., 2020). Tn-Seq would allow us to identify
all mutants that permit intramacrophage growth in cells lacking PmrA (including those in
PriM) and quantify their relative abundance, providing a genome-wide screen of factors
necessary for PriM to function as an anti-virulence factor.

Why does the mutation in the ATP-binding protein FTL_0146 allow for increased
intramacrophage growth?
Finally, we would like to determine why the mutation of the ATP-binding protein
FTL_0146 permits increased intramacrophage growth. We found that the mutation in
FTL_0146 present in the ΔpmrA suppressor strain provided an intramacrophage growth
benefit when recreated in both the wildtype background as well as the ΔpmrA
background, suggesting that it provides a growth advantage to cells growing in
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macrophage regardless of the presence or absence of PmrA. It is possible that the
mutation in FTL_0146 alters the efficiency of substrate transport; however, the substrate
for the predicted ABC transport system comprised of FTL_0145 and FTL_0146 is
unknown. To investigate the function of this transport system, we will identify interaction
partners of this putative ABC transport system by immunoprecipitating each known
component (the proteins encoded by FTL_0145 and FTL_0146) and identify co-purifying
proteins by mass spectrometry. Ideally this experiment will shed light on the role of this
ABC transport system in LVS.
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